Theravance Biopharma’s Record-Breaking Year: YUPELRI and TRELEGY
Theravance Biopharma, a biopharmaceutical company, reported impressive financial results for the fourth quarter and full-year ended December 31, 2024. The company collaborated closely with Viatris to achieve record net sales for YUPELRI® (revefenacin), a once-daily, long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
YUPELRI Net Sales Reach All-Time High
In the fourth quarter of 2024, YUPELRI net sales reached an all-time high of $66.7 million, marking a 10% increase compared to the same period in 2023. For the full-year 2024, YUPELRI net sales totaled $238.6 million, representing an 8% increase compared to 2023.
TRELEGY Sales Milestones and Collaboration with GSK
Additionally, Theravance Biopharma achieved $50 million in TRELEGY® related sales milestones, following the announcement of strong sales figures from GSK. TRELEGY, a once-daily, fixed-dose combination of fluticasone fumarate and vilanterol trifluoromethoxyphenylmethanesulfonate, is used for the long-term, once-daily maintenance treatment of airflow obstruction in COPD, and reduction of exacerbations in patients with COPD and asthma.
CYPRESS Study Update
The CYPRESS study, a Phase 3b, open-label, long-term safety study of YUPELRI, is on track to enroll its final patient in the open label portion by mid-2025.
Financial Position
As of December 31, 2024, Theravance Biopharma ended the year with $88 million in cash, excluding the $50 million TRELEGY milestone. The cash receipt for the milestone is expected in February 2025.
Impact on Individuals
For individuals living with COPD, the success of YUPELRI and TRELEGY could mean improved treatment options and better management of their condition. These medications offer long-term maintenance treatment and reduction of exacerbations, leading to improved quality of life and potential cost savings through fewer hospitalizations and emergency room visits.
Impact on the World
Globally, the COPD population is projected to reach 380 million by 2030. The success of YUPELRI and TRELEGY could lead to better disease management for millions of people, reducing the burden on healthcare systems and increasing productivity.
Conclusion
Theravance Biopharma’s record-breaking year, marked by the success of YUPELRI and TRELEGY, represents a significant milestone in the treatment of COPD. The collaborative efforts between Theravance Biopharma and Viatris, as well as the ongoing CYPRESS study, are promising signs for the future of COPD management. For individuals living with COPD, this could mean improved treatment options and better quality of life. For the world, it could lead to cost savings and a reduction in the burden on healthcare systems.
- Record-breaking YUPELRI net sales of $66.7 million in Q4 2024 and $238.6 million in FY 2024
- Collaboration with Viatris leading to profitability and sales milestones for YUPELRI
- TRELEGY sales reaching $3.46 billion in FY 2024, triggering a $50 million milestone for Theravance Biopharma
- CYPRESS study on track to enroll final patient in open label portion by mid-2025
- Ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone
- Improved treatment options and better quality of life for individuals living with COPD
- Reduction in burden on healthcare systems and cost savings for the world
